Artivion, Inc. AORT
We take great care to ensure that the data presented and summarized in this overview for ARTIVION, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AORT
View all-
Black Rock Inc. New York, NY6.64MShares$303 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.03MShares$138 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C32.48MShares$114 Million0.13% of portfolio
-
Morgan Stanley New York, NY2.24MShares$102 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.02MShares$92.3 Million0.19% of portfolio
-
State Street Corp Boston, MA1.54MShares$70.4 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA1.5MShares$68.6 Million0.01% of portfolio
-
Juniper Investment Company, LLC New York, NY1.33MShares$60.9 Million22.95% of portfolio
-
Fred Alger Management, LLC New York, NY1.32MShares$60.2 Million0.25% of portfolio
-
Next Century Growth Investors LLC Minneapolis, MN1.05MShares$47.9 Million3.69% of portfolio
Latest Institutional Activity in AORT
Top Purchases
Top Sells
About AORT
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Insider Transactions at AORT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,572
-3.4%
|
$201,168
$44.42 P/Share
|
|
Dec 03
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
30,921
-3.72%
|
$1,391,445
$45.46 P/Share
|
|
Dec 03
2025
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,921
+3.58%
|
$896,709
$29.62 P/Share
|
|
Dec 03
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
7,315
-2.26%
|
$329,175
$45.3 P/Share
|
|
Dec 02
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
30,921
-3.72%
|
$1,391,445
$45.56 P/Share
|
|
Dec 02
2025
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,921
+3.58%
|
$896,709
$29.62 P/Share
|
|
Dec 01
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Bona fide gift
|
Direct |
750
-0.55%
|
-
|
|
Nov 21
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
47,376
-18.89%
|
$2,131,920
$45.13 P/Share
|
|
Nov 21
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Exercise of conversion of derivative security
|
Direct |
47,376
+25.58%
|
$663,264
$14.74 P/Share
|
|
Nov 20
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
15,276
-9.42%
|
$672,144
$44.24 P/Share
|
|
Nov 20
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Exercise of conversion of derivative security
|
Direct |
3,388
+3.51%
|
$47,432
$14.74 P/Share
|
|
Nov 18
2025
|
Elizabeth A Hoff Director |
SELL
Open market or private sale
|
Direct |
4,200
-13.38%
|
$189,000
$45.1 P/Share
|
|
Nov 17
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,394
-3.77%
|
$287,730
$45.17 P/Share
|
|
Nov 17
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,394
+3.63%
|
$185,426
$29.62 P/Share
|
|
Nov 17
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,394
-3.12%
|
$287,730
$45.17 P/Share
|
|
Nov 17
2025
|
John E Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,394
+3.02%
|
$185,426
$29.62 P/Share
|
|
Nov 17
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
6,000
-4.24%
|
$270,000
$45.73 P/Share
|
|
Nov 14
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,393
-3.77%
|
$287,685
$45.0 P/Share
|
|
Nov 14
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,393
+3.63%
|
$185,397
$29.62 P/Share
|
|
Nov 14
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,393
-3.12%
|
$281,292
$44.67 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 500K shares |
|---|---|
| Exercise of conversion of derivative security | 323K shares |
| Open market or private purchase | 2.1K shares |
| Open market or private sale | 621K shares |
|---|---|
| Bona fide gift | 750 shares |